

9th InterAmerican Oncology Conference
"Current Status and Future of Anticancer Therapies"
July 9-10, 2021

The 9th Conference of IAOC "Current Status and Future of Anti-Cancer Therapies" will be held virtually in July 9-10, 2021.

The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.

The virtual format will include a two day live program, where attendees will be able to view presentations, hear live audio, and interact online, as well as on demand sessions. All sessions presented live will be recorded and both the recorded live sessions and the on demand sessions will be made available to attendees for 1 month.

The presentations will be in English and Spanish and will be translation into both languages in real time for the attendees. Sessions will be recorded and streamed live to allow participation delegates from all over the world to participate in live Q&A with faculty and session chairs.

Based on previous experience, we anticipate attendance by more than 3000 scientists, practicing oncologists, basic and clinical translational investigators, hematologists and health care workers from Latin America, USA and Europe.

CONFERENCE CO-CHAIRS

Alex Adjei, Rochester, USA
Román Perez Soler, New York, USA
Antoni Ribas, Los Angeles, USA
Josep Tabernero, Barcelona, Spain

SCIENTIFIC COMMITTEE

Alex Adjei, MD, Ph.D, Mayo Clinic, Rochester, USA
Carlos L. Arteaga, MD, Harold C. Simmons Cancer Center, Texas, USA
Kenneth C. Anderson, MD, Dana-Farber Cancer Institute Boston, Massachusetts, USA
Carlos H. Barrios, MD, Hospital São Lucas, Porto Alegre , Brazil
Luis Paz Ares, MD, Hospital Universitario 12 de Octubre Madrid Spain
Roman Perez Soler, MD, Albert Einstein College of Medicine, New York, USA
Antoni Ribas, MD, Ph.D, UCLA, Los Angeles, USA
Josep Tabernero, MD, Ph.D, Vall d'Hebron University Hospital, Barcelona, Spain

PRELIMINARY PROGRAM

NEW ANTICANCER THERAPIES

Management of Immune Related Adverse Events from Immune Checkpoint

Jarushka Naidoo, Baltimore, USA

Why it is Important to have a Multidisciplinary Approach in Precision Medicine

Christian Rolfo, Baltimore, USA

Promising New Agents in Cancer Therapy

Alex A. Adjei, Rochester, USA

BREAST & GYNECOLOGICAL CANCER

Management of HER2/neu Positive Breast Cancer

Carlos Barrios, Porto Alegre, Brazil

Management of ER/PR Positive Breast Cancer

Ingrid A. Mayer, Nashville, USA

Novel Approaches in the Management of Ovarian and Cervical Cancer

Robert Coleman, Houston, USA

MELANOMA

New Treatments and Current Management in Melanoma

Antoni Ribas, California, USA

GU CANCER

Advances in Treating Metastatic Prostate Cancer

Johann de Bono, London, UK

Novel Therapies in Renal and Urothelial Cancers

Joaquim Bellmunt, Boston, USA

GI CANCER

Management of CRC

Josep Tabernero, Barcelona, Spain

Management of advanced Hepatocellular and Hepatobiliary Carcinomas

Josep Llovet, New York, USA

Advances in the Management of Advanced Esophageal/GEJ/Gastric cancer

Josep Tabernero, Barcelona, Spain

LUNG CANCER

Management of Locally Advanced NSCLC

Luis Paz Ares, Madrid, Spain

Management of Metastatic NSCLC

Enriqueta Felip, Barcelona, Spain

Management of SCLC and Mesothelioma

Julie Brahmer, Baltimore, USA

HEMATOLOGICAL MALIGNANCIES

Lymphoma

Stephen Ansell, Rochester, USA

Multiple Myeloma

Kenneth C. Anderson, Boston, USA

Leukemia CML

Jorge Cortés, Georgia, USA

Therapeutic Progress in MDS and AML

Guillermo Garcia-Manero, Houston, USA

CONFERENCE SECRETARIAT

Secretariat@oncologyconferences.com.ar

www.oncologyconferences.org